Green tea deserves special mention: its catechins (especially EGCG) have been shown to inhibit DPP-IV activity in adipose tissue (view study), potentially preserving GLP-1 levels by slowing its breakdown the same mechanism targeted by DPP-IV inhibitor drugs
Given the explorative nature of the present study and the primary focus on C8-carnitine (with other acyl-carnitines as secondary endpoints), we did not apply multiple comparison corrections for the primary analysis
In addition, similar to other GLP-1 RAs, it affects different stages of the pathophysiological process of CVDs, from risk factors like dyslipidemia, hypertension, obesity, diabetes, and coronary artery atherosclerosis to more advanced stages such as myocardial ischemia, atherothrombosis, myocardial infarction, left ventricular remodeling, and death, without raising the risk of arrhythmia, hospitalization, or exacerbating heart failure [35, 41]
FAQs How do you microdose with GLP-1
Quitting semaglutide abruptly can lead to semaglutide withdrawal and other adverse effects